The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy

Autor: Isaksen, Kathrine Thuestad, Galleberg, Renate Berget, Mastroianni, Maria Adele, Rinde, Marit, Rusten, Leiv Sindre, Barzenje, Dlawer Abdulla, Ramslien, Lloyd Frode, Fluge, Øystein, Jordhøy, Marit Slaaen, Meyer, Peter Albert, Liestøl, Knut, Smeland, Erlend Bremertun, Lingjærde, Ole Christian, Holte, Harald, Brodtkorb, Marianne

Externí odkaz: https://hdl.handle.net/11250/3117354

Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination

Autor: Riise, Jon, Meyer, Saskia, Blaas, Isaac, Chopra, Adity, Tran, Trung, Delic-Sarac, Marina, Hestdalen, Malu Lian, Brodin, Ellen Elisabeth, Rustad, Even Holth, Dai, Ke-Zheng, Vaage, John T., Nissen-Meyer, Lise Sofie Haug, Sund, Fredrik, Wader, Karin Fahl, Bjørnevik, Anne Turid, Meyer, Peter Albert, Nygaard, Gro Owren, König, Marton, Smeland, Sigbjørn, Lund-Johansen, Fridtjof, Olweus, Johanna, Kolstad, Arne

Publikováno v: Riise, Jon Meyer, Saskia Blaas, Isaac Chopra, Adity Tran, Trung Delic-Sarac, Marina Hestdalen, Malu Lian Brodin, Ellen Elisabeth Rustad, Even Holth Dai, Ke-Zheng Vaage, John T. Nissen-Meyer, Lise Sofie Haug Sund, Fredrik Wader, Karin Fahl Bjørnevik, Anne Turid Meyer, Peter Albert Nygaard, Gro Owren König, Marton Smeland, Sigbjørn Lund-Johansen, Fridtjof Olweus, Johanna Kolstad, Arne . Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. British Jo
British Jo

Externí odkaz: http://hdl.handle.net/10852/97611

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Autor: Leppä, Sirpa, Jørgensen, Judit, Tierens, Anne, Meriranta, Leo, Østlie, Ingunn, Brown, Peter de Nully, Fagerli, Unn-Merete, Larsen, Thomas Stauffer, Mannisto, Susanna, Munksgaard, Lars, Maisenhölder, Martin, Vasala, Kaija, Meyer, Peter Albert, Jerkeman, Mats, Björkholm, Magnus, Fluge, Øystein, Jyrkkiö, Sirkku, Liestøl, Knut, Ralfkiaer, Elisabeth, Spetalen, Signe, Beiske, Klaus, Karjalainen-Lindsberg, Marja-Liisa, Holte, Harald

Publikováno v: Leppä, Sirpa Jørgensen, Judit Tierens, Anne Meriranta, Leo Østlie, Ingunn Brown, Peter de Nully Fagerli, Unn-Merete Larsen, Thomas Stauffer Mannisto, Susanna Munksgaard, Lars Maisenhölder, Martin Vasala, Kaija Meyer, Peter Albert Jerkeman, Mats Björkholm, Magnus Fluge, Øystein Jyrkkiö, Sirkku Liestøl, Knut Ralfkiaer, Elisabeth Spetalen, Signe Beiske, Klaus Karjalainen-Lindsberg, Marja-Liisa Holte, Harald . Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Advances. 2020, 4(9), 1906-1915
Blood Advances

Externí odkaz: http://hdl.handle.net/10852/85450
https://www.duo.uio.no/bitstream/handle/10852/85450/1/Postnr%2B1890786_Lepp%25C3%25A4%2Bet%2Bal_Blood%2BAdvances_2020001518.pdf